Daiichi Sankyo invests $1B to bulk out German site for cancer ADCs
20 Feb 2024
ADC
Daiichi Sankyo is pouring €1 billion ($1.07 billion) into a German facility in part to expand its capacity for antibody-drug conjugate manufacturing. The first part of the expansion became operational last month, a company spokesperson told Endpoints News.
The facility is in Pfaffenhofen an der Ilm, which is a 40-minute drive north of Munich. The Japanese pharma will build a new lab for cancer ADCs that will be finished by 2026 in addition to bolstering cardiovascular disease asset production. There is “increased global demand for ADC cancer therapies,” added Daiichi Europe site manager Matthias Kühn in the press release.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.